





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : C07D 207/00, 401/00, C07K 5/00</p>	A2	<p>(11) International Publication Number: <b>WO 98/19998</b> (43) International Publication Date: 14 May 1998 (14.05.98)</p>
<p>(21) International Application Number: PCT/EP97/06125 (22) International Filing Date: 5 November 1997 (05.11.97) (30) Priority Data: 08/746,295 7 November 1996 (07.11.96) US (71) Applicant (for all designated States except US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH). (72) Inventor; and (75) Inventor/Applicant (for US only): VILLHAUER, Edwin, Bernard [US/US]; 20 Dorothy Drive, Morristown, NJ 07960 (US). (74) Agent: ROTH, Bernhard, M.; Novartis AG, Patent- und Markenabteilung, Lichtstrasse 35, CH-4002 Basel (CH).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: N-SUBSTITUTED 2-CYANOPYRROLIDINES</p> <p>(57) Abstract</p> <p>N-(N'-substituted glycyloxy)-2-cyanopyrrolidines, e.g. the compounds of formula (I) wherein R has various significances, are novel. They inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.</p> <div style="text-align: right;">  <p>(I)</p> </div> <div style="text-align: right; margin-top: 20px;">  </div>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## N-SUBSTITUTED 2-CYANOPYRROLIDINES

### Field

The present invention relates to N-substituted 2-cyanopyrrolidines. More particularly, it provides novel N-glycyl-2-cyanopyrrolidine derivatives.

### Background

Dipeptidyl peptidase-IV (**DPP-IV**) is a serine protease which cleaves N-terminal dipeptides from a peptide chain containing, preferably, a proline residue in the penultimate position. Although the biological role of DPP-IV in mammalian systems has not been completely established, it is believed to play an important role in neuropeptide metabolism, T-cell activation, attachment of cancer cells to the endothelium and the entry of HIV into lymphoid cells. DPP-IV is responsible for inactivating glucagon-like peptide-1 (**GLP-1**). More particularly, DPP-IV cleaves the amino-terminal His-Ala dipeptide of GLP-1, generating a GLP-1 receptor antagonist, and thereby shortens the physiological response to GLP-1. Since the half-life for DPP-IV cleavage is much shorter than the half-life for removal of GLP-1 from circulation, a significant increase in GLP-1 bioactivity (5- to 10-fold) is anticipated from DPP-IV inhibition. Since GLP-1 is a major stimulator of pancreatic insulin secretion and has direct beneficial effects on glucose disposal, DPP-IV inhibition appears to represent an attractive approach for treating non-insulin-dependent diabetes mellitus (**NIDDM**).


Although a number of DPP-IV inhibitors have been described, all have limitations relating to potency, stability or toxicity. Accordingly, a great need exists for novel DPP-IV inhibitors which are useful in treating conditions mediated by DPP-IV inhibition and which do not suffer from the above-mentioned limitations.

**Summary of the invention**

The invention provides novel N-(N'-substituted glycy)-2-cyanopyrrolidines which are effective as DPP-IV inhibitors in treating conditions mediated by DPP-IV. It also concerns corresponding pharmaceutical compositions, a process for their preparation, a method of inhibiting DPP-IV comprising administering to a patient in need of such treatment a therapeutically effective amount thereof, the compounds for use as a pharmaceutical, and their use in a process for the preparation of a medicament for treating a condition mediated by DPP-IV.

**Detailed description**

The invention concerns N-(N'-substituted glycy)-2-cyanopyrrolidines, hereinafter briefly named "**the compounds of the invention**"; more particularly, it concerns compounds of formula I:



wherein **R** is:

a)  $R_1R_{1a}N(CH_2)_m$ - wherein

$R_1$  is a pyridinyl or pyrimidinyl moiety optionally mono- or independently disubstituted with (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy, halogen, trifluoromethyl, cyano or nitro; or phenyl optionally mono- or independently disubstituted with (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy or halogen;

$R_{1a}$  is hydrogen or (C<sub>1-8</sub>)alkyl; and

$m$  is 2 or 3;

b) (C<sub>3-12</sub>)cycloalkyl optionally monosubstituted in the 1-position with (C<sub>1-3</sub>)hydroxyalkyl;

c)  $R_2(CH_2)_n$ - wherein either

$R_2$  is phenyl optionally mono- or independently di- or independently trisubstituted with (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy, halogen or phenylthio optionally monosubstituted in the phenyl ring with hydroxymethyl; or is (C<sub>1-8</sub>)alkyl; a [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with (C<sub>1-8</sub>)alkyl;

a pyridinyl or naphthyl moiety optionally mono- or independently disubstituted with (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy or halogen; cyclohexene; or adamantyl; and

n is 1 to 3; or

R<sub>2</sub> is phenoxy optionally mono- or independently disubstituted with (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy or halogen; and

n is 2 or 3;

- d) **(R<sub>3</sub>)<sub>2</sub>CH(CH<sub>2</sub>)<sub>2</sub>-** wherein each R<sub>3</sub> independently is phenyl optionally mono- or independently disubstituted with (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy or halogen;
- e) **R<sub>4</sub>(CH<sub>2</sub>)<sub>p</sub>-** wherein R<sub>4</sub> is 2-oxopyrrolidinyl or (C<sub>2-4</sub>)alkoxy and p is 2 to 4;
- f) **isopropyl** optionally monosubstituted in 1-position with (C<sub>1-3</sub>)hydroxyalkyl;
- g) **R<sub>5</sub>** wherein R<sub>5</sub> is: indanyl; a pyrrolidinyl or piperidinyl moiety optionally substituted with benzyl; a [2.2.1]- or [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with (C<sub>1-8</sub>)alkyl; adamantyl; or (C<sub>1-8</sub>)alkyl optionally mono- or independently plurisubstituted with hydroxy, hydroxymethyl or phenyl optionally mono- or independently disubstituted with (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy or halogen;
- in free form or in acid addition salt form.

The compounds of formula I can exist in free form or in acid addition salt form. Salt forms may be recovered from the free form in known manner and vice-versa. Acid addition salts may e.g. be those of pharmaceutically acceptable organic or inorganic acids. Although the preferred acid addition salts are the hydrochlorides, salts of methanesulfonic, sulfuric, phosphoric, citric, lactic and acetic acid may also be utilized.

The compounds of the invention may exist in the form of optically active isomers or diastereoisomers and can be separated and recovered by conventional techniques, such as chromatography.

"Alkyl" and "alkoxy" are either straight or branched chain, of which examples of the latter are isopropyl and tert-butyl.

R preferably is a), b) or e) as defined above. R<sub>1</sub> preferably is a pyridinyl or pyrimidinyl moiety optionally substituted as defined above. R<sub>1a</sub> preferably is hydrogen. R<sub>2</sub> preferably is phenyl optionally substituted as defined above. R<sub>3</sub> preferably is unsubstituted phenyl.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.